Kerala Ayurveda Allots Shares Against ₹12.47 Crore Loan
Key highlights
- Kerala Ayurveda Limited allotted 6,55,000 shares at ₹190.37 each against about ₹12.47 crore of unsecured loan.
- The company completed a ₹30.66 crore preferential issue of 9,34,887 shares on 21 March 2026.
- The March 2026 allotment increased paid-up capital from ₹12.06 crore to about ₹13.00 crore.
- Promoters held 35.6% and public shareholders held 64.4% as of 13 November 2026.
powered by IRIS

Kerala Ayurveda Limited allotted 6,55,000 equity shares at ₹190.37 each to promoter-group entity Katra Holding Private Limited, partly converting an unsecured loan of ₹12.47 crore into equity. The transaction follows the company’s ₹30.66 crore preferential issue approved during FY26, which also enabled full ownership of Ayurvedagram.
Know Kerala Ayurveda inside out
Results, valuation, peers and who's buying, in one view.
What shares did Kerala Ayurveda allot against the loan?
Kerala Ayurveda Limited issued 6,55,000 equity shares to Katra Holding Private Limited at ₹190.37 per share. The allotment partly adjusted an existing unsecured loan of ₹12,46,92,350, or about ₹12.47 crore, owed by the company to the promoter-group entity.
The stated issue price and number of shares imply a consideration broadly matching the portion of the loan converted into equity. Debt conversion replaces a defined part of a company’s borrowing obligation with share capital. In this case, Katra Holding receives equity shares while the corresponding unsecured loan balance is adjusted to the extent specified in the allotment.
Katra Holding is identified as a promoter-group entity in the disclosed information. The transaction is therefore relevant to investors assessing the company’s capital structure, outstanding related funding arrangements and promoter-group ownership.
The source does not provide a market-price reaction, trading-volume data or a revised promoter holding immediately after this specific 6,55,000-share allotment. It also does not disclose the remaining unsecured loan balance after the partial adjustment.
How did the ₹30.66 crore preferential issue unfold?
Kerala Ayurveda Limited completed a preferential allotment of 9,34,887 equity shares on 21 March 2026, following shareholder consideration of the proposal at an extraordinary general meeting scheduled for 14 March 2026. The issue had an aggregate value of ₹30.66 crore and combined a loan-conversion component with consideration for a subsidiary stake acquisition.
Of the total shares allotted in March, 6,30,000 shares were issued to Katra Holding for conversion of existing loans. This component was valued at ₹20,66,33,700. The balance of 3,04,887 shares, valued at ₹9,99,99,887.13, was issued to individual shareholders to acquire an additional 26% stake in Ayurvedagram Heritage Wellness Centre Private Limited.
The board had approved the proposed preferential issue on 12 February 2026, alongside its approval of third-quarter FY26 financial results. The EGM agenda also included amendments to the company’s ESOP 2023 plan, although the supplied information does not state the final outcome of those amendments.
The March allotment increased paid-up capital from ₹12,06,01,980 to ₹12,99,50,850. It also made Ayurvedagram a wholly owned subsidiary of Kerala Ayurveda Limited, bringing the remaining minority interest in the wellness-centre business under the company’s ownership.
Why did Kerala Ayurveda acquire full ownership of Ayurvedagram?
Kerala Ayurveda Limited acquired the additional 26% interest in Ayurvedagram Heritage Wellness Centre Private Limited through the 3,04,887-share issuance to individual shareholders. Following completion, Ayurvedagram became a wholly owned subsidiary of KAL.
Full ownership gives KAL complete control over the subsidiary rather than shared ownership with minority shareholders. The supplied disclosures establish the ownership outcome and the share-based consideration, but do not provide separate revenue, profit, valuation or cash-flow figures for Ayurvedagram Heritage Wellness Centre.
The company has separately described growth in its health-service business. Its disclosed material says consolidated FY25 revenue rose 22% year on year, or 17.4% excluding Ayurvedagram Bali and Om Vedic Singapore. No absolute FY25 revenue figure was supplied, so the reported growth rates are the available basis for assessing the trend.
KAL also said its earlier revenue grew 21%, or 16% excluding Ayurvedagram Bali, supported by health services and India and US e-commerce. These statements provide context for the company’s focus on wellness services, digital channels and international partnerships, though they do not quantify the contribution of the Indian Ayurvedagram subsidiary.
Got a follow-up? Ask IRIS
What is Kerala Ayurveda doing outside India?
Kerala Ayurveda Limited has pursued overseas wellness partnerships through its wholly owned subsidiary Nutraveda PTE LTD. In December 2025, Nutraveda entered a 50:50 joint venture with Monica Mohindra to establish Pt. Kerala Ayurveda Bali in Indonesia.
The Bali joint venture is intended to operate in sports education, wellness and hospitality services. Its authorised share capital is IDR 10 billion and its paid-up capital is IDR 2.5 billion. Nutraveda and Monica Mohindra each hold 1,250 shares, representing equal ownership in the venture.
The joint-venture agreement includes transfer restrictions. A shareholder seeking to transfer shares must first offer them to the existing shareholder at the proposed price. Third-party transfers can occur after the offer period expires and require approval at a general meeting, while capital-structure changes are subject to shareholder approval and applicable regulations.
KAL has said the transaction was not a related-party transaction and was structured to comply with applicable SEBI Listing Regulations. Its disclosures also refer to plans to restructure the 50:50 Bali venture to consolidate Ayurvedagram Bali revenue into KAL, but do not give a completion date for that restructuring.
How do these transactions affect Kerala Ayurveda investors?
The preferential allotments increased KAL’s share capital and used equity rather than cash to address part of its unsecured loan funding and acquire the residual Ayurvedagram stake. For shareholders, this means the share count rose, while the company reduced or adjusted liabilities to the extent of the debt conversion.
The effect on per-share financial metrics cannot be calculated from the available disclosures because they do not include the total post-allotment share count, profit figures, loan balance after adjustment, or current market price. There is also no share-price performance data in the source material, so no conclusion can be drawn about the market’s immediate response.
Shareholding data as of 13 November 2026 show promoters holding 35.6% and public shareholders holding 64.4%. This reported split is a useful ownership reference, although the data supplied does not break out Katra Holding’s individual stake or compare it with its holding before the latest allotment.
The wider operational picture includes international expansion and subsidiary consolidation. KAL stated that partnerships involving Om Vedic Singapore and the integration of Ayurvedagram Bali could contribute an additional ₹20 crore in the next fiscal year. It separately referred to a Think Bali Hospitality joint venture projected to close in Q3 and expected to add ₹4 crore, but these are company projections rather than recorded financial results.
Conclusion
Kerala Ayurveda Limited’s equity allotments show a capital-structure strategy that combines partial debt conversion with the acquisition of full ownership of Ayurvedagram. The completed ₹30.66 crore preferential issue in March 2026 raised paid-up capital and brought the remaining 26% interest in the subsidiary into KAL, while the separate 6,55,000-share allotment adjusted about ₹12.47 crore of unsecured borrowing from Katra Holding.
Investors can watch for disclosures on the outstanding loan balance after the partial conversion, changes in promoter-group ownership, and the planned restructuring to consolidate Ayurvedagram Bali revenue. KAL’s stated targets of an additional ₹20 crore from global partnerships and ₹4 crore from the proposed Think Bali Hospitality venture will also require subsequent operational and financial updates.


